Related Experiment Video
Updated: Aug 14, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Fungal chemoprophylaxis with fluconazole in preterm infants
José Manuel Martínez Sesmero1, Francisco José Farfán Sedano, Teresa Molina García
1Department of Pharmacy, Getafe University Hospital Ctra., de Toledo km 12,500, 28905, Getafe, Madrid, Spain. mano24@ono.com
Insights
Fluconazole chemoprophylaxis is safe and well-tolerated in very low birth weight (VLBW) infants. This antifungal treatment effectively prevented fungal infections in VLBW infants, suggesting potential to reduce mortality.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Very low birth weight (VLBW) infants are highly susceptible to fungal infections.
- Establishing effective antifungal chemoprophylaxis is crucial for improving outcomes in this vulnerable population.
Purpose of the Study:
- To establish a fungal chemoprophylaxis protocol for VLBW infants.
- To evaluate the safety, tolerability, and effectiveness of fluconazole in VLBW infants.
Main Methods:
- A protocol was developed based on MEDLINE literature search (1994-2001).
- Inclusion criteria: gestational age <28 weeks and birth weight <1500 g.
- Fluconazole administered intravenously; pharmacotherapeutic follow-up for 1 year.
Main Results:
- Sixteen VLBW infants were enrolled; two deaths unrelated to study drugs.
- No significant drug interactions or fluconazole side effects were reported.
- No fungal infections occurred in infants completing chemoprophylaxis.
Conclusions:
- Fluconazole demonstrated excellent safety and tolerability in VLBW infants.
- The absence of fungal infections suggests fluconazole's potential to reduce VLBW morbidity and mortality.
Introduction:
To describe the establishment of a fungal chemoprophylaxis protocol in very low birth weight infants (VLBW). To asses safety, tolerability, and effectiveness of fluconazole administration to these patients.
Method:
According to published scientific evidence (search on MEDLINE 1994-2001) inclusion criteria for the protocol were defined: gestational age <28 weeks and birth weight <1500 g. Fluconazole was given intravenously by infusion. A pharmacotherapeutic follow-up of patients included on the protocol was performed for 1 year.
Results:
Sixteen patients were included on the protocol, two of them died because of causes not related to the drugs given. Significant drug interactions were not observed. Fluconazole side effects were not reported either. None of the patients who finished the chemoprophylaxis showed signs or symptoms of fungal infection.
Conclusion:
Fluconazole chemoprophylaxis in this small number of patients has shown an excellent safety and tolerability profile. The lack of fungal infection points out the possibility of using fluconazole to reduce morbidity and mortality in VLBW.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Drug Dosing: Infants and Children
Candidiasis
Respiratory Syncytial Virus Disease

